News Snapshot:
Everest gains access to a clinically-validated mRNA platform and a potentially "best-in-class" mRNA COVID-19 vaccine with full technology transfer Everest and Providence to enter into a 50/50 worldwide collaboration to jointly develop two additional products, leveraging Providence's cutting-edge mRNA technology Collaboration accelerates the expansion of Everest's discovery capabilities and enables Everest to develop additional mRNA-based products with global rights SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest" or the "Company") announced today two separate definitive agreements ("Agreements") with Providence Therapeutics Holdings Inc. ("Providence"), a clinical stage biotechnology company developing messenger RNA ("mRNA") therapeutics and vaccines, to...
